|
A systematic review of the clinical effectiveness and cost effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy |
Hockenhull J, Elremeli M, Cherry MG, Mahon J, Lai M, Darroch J, Oyee J, Boland A, Dickson R, Dundar Y, Boyle R
|
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hockenhull J, Elremeli M, Cherry MG, Mahon J, Lai M, Darroch J, Oyee J, Boland A, Dickson R, Dundar Y, Boyle R
. A systematic review of the clinical effectiveness and cost effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. Health Technology Assessment 2012; 16(12): 1-109 Authors' conclusions Study found that the current use of Pharmalgen® venom immunotherapy in clinical practice in the NHS appears to be based on limited and poor-quality clinical effectiveness research. Pharmalgen® may be cost-effective for a subgroup of patients at high risk of future stings and a subgroup in whom Pharmalgen® improves quality of life owing to reduced anxiety. Indexing Status Subject indexing assigned by CRD MeSH Antigens, Dermatophagoides; Bee Venoms; Cost-Benefit Analysiss; Hypersensitivity; Wasp Venoms Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32011001140 Date abstract record published 28/09/2011 |
|
|
|